Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Net Cash Flow data on file, last reported at -$496000.0 in Q2 2026.

• Quarterly Net Cash Flow fell 100.75% year-over-year to -$496000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $609.8 million (up 479.16% YoY) and the FY2025 annual result came in at $655.2 million, up 287.69% from the prior year.
• Net Cash Flow declined to -$496000.0 in Q2 2026, from $60.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $495.6 million in Q3 2022 to a low of -$283.7 million in Q1 2022.
• A 5-year average of $48.8 million and a median of $44.9 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow slumped 150.73% — and 2024, when it surged 2124.43%.
• Tracing ALNY's Net Cash Flow over 5 years: stood at -$208.5 million in 2022, then declined by 10.92% to -$231.2 million in 2023, then soared by 49.58% to -$116.6 million in 2024, then surged by 247.29% to $171.7 million in 2025, then tumbled by 100.29% to -$496000.0 in 2026.
• The last three Net Cash Flow figures came in at -$496000.0 (Q2 2026), $60.7 million (Q1 2026), and $171.7 million (Q4 2025), per Business Quant data.